Synthetic VHH libraries are becoming an increasingly important route for antibody discovery, offering a faster, more controlled alternative to traditional immunisation-based workflows. But for drug developers, speed alone is not enough: discovery platforms must generate binders with the affinity, stability, diversity and early developability characteristics needed to support therapeutic discovery programmes.
In this whitepaper, Isogenica presents a data-driven validation of its synthetic VHH antibody libraries, powered by Colibra® technology. Written for biotech and pharmaceutical scientists, the paper evaluates library performance across key discovery criteria, including binding affinity, biophysical stability, solubility, aggregation behaviour and thermal robustness.
The whitepaper highlights the ability of Isogenica’s synthetic VHH libraries to generate diverse lead panels against human targets, including cell-surface receptors and oncology antigens. It also covers kinetic assessment using technologies such as Octet and SPR, alongside high-throughput expression and purification workflows.
A key focus is developability. The paper discusses how rigorous biophysical screening, parallel selection and controlled in vitro discovery can help identify novel, patentable sequences with favourable early developability characteristics.
For teams working in oncology, immunotherapy or advanced biologic formats, the whitepaper provides a practical evidence base for the use of synthetic VHH libraries in early discovery.
Read the full whitepaper: https://isogenica.com/white-paper-validation-synthethic-vhhs/